China's Zai Lab rises on product inclusion in National Reimbursement Drug List

CStone Pharmaceuticals

13/12/2023 07:53

** Shares of Zai Lab  9688.HK  rise 5.4% to HK$21.60, set
for biggest one-day pct rise since Nov. 15, if gains hold
    ** Biopharma co says its product VYVGART® (efgartigimod alfa
injection) has been included in China's 2023 National
Reimbursement Drug List, bringing co's products in the list to a
total of 4
    ** Shanghai-based co commercially launched VYVGART in
mainland China in September 2023 and has an exclusive license to
develop and commercialize efgartigimod in mainland China, Hong
Kong, Macau, and Taiwan
    ** Hutchmed  0013.HK  and CStone Pharmaceuticals  2616.HK ,
among others, climb 0.7% and 1.1%, respectively, after some of
their products are updated to be included in the list   
    ** Hong Kong's healthcare index  .HSCIH  slips 0.5%, Hang
Seng Composite Index  .HSCI  falls 1.2%, Hang Seng Index  .HSI 
down 1.1%
    ** Zai Lab down 12.2% YTD 

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))